Company Overview - Hongri Pharmaceutical (SZ 300026) announced its ninth board meeting on December 12, 2025, in Tianjin, discussing the amendment of the company's articles of association [1] Revenue Composition - For the year 2024, the revenue composition of Hongri Pharmaceutical is as follows: - Traditional Chinese medicine formula granules and decoction pieces account for 46.15% - Finished drugs account for 24.72% - Medical devices account for 19.39% - Auxiliary materials and raw materials account for 8.33% - Other industries account for 1.42% [1] Market Capitalization - As of the report, Hongri Pharmaceutical has a market capitalization of 10.9 billion yuan [1]

Group 1 - The core point of the news is that Hongri Pharmaceutical announced a share reduction plan by major shareholders and senior management, indicating potential changes in ownership structure [1] - Shareholder Yao Xiaoqing, holding approximately 300 million shares (10% of total shares), plans to reduce holdings by up to 46.94 million shares (1.5624% of total shares) within three months after the announcement [1] - Senior management members Chen Ruiqiang and Zhang Kun plan to reduce their holdings by up to 170,000 shares (0.0056% of total shares) and 230,000 shares (0.0077% of total shares) respectively, also within three months after the announcement [1] Group 2 - For the fiscal year 2024, Hongri Pharmaceutical's revenue composition is as follows: Traditional Chinese medicine formula granules and decoction pieces account for 46.15%, finished drugs 24.72%, medical devices 19.39%, excipients and raw materials 8.33%, and other industries 1.42% [2] - As of the latest report, Hongri Pharmaceutical has a market capitalization of 11.4 billion yuan [3]

Company Overview - Hongri Pharmaceutical (SZ 300026) announced its third board meeting of the ninth session held on October 27, 2025, in Tianjin, where the agenda included the discussion of the 2025 Q3 report [1] - As of the report, Hongri Pharmaceutical has a market capitalization of 11.4 billion yuan [1] Revenue Composition - For the year 2024, the revenue composition of Hongri Pharmaceutical is as follows: - Traditional Chinese medicine formula granules and decoction pieces account for 46.15% - Finished drugs account for 24.72% - Medical devices account for 19.39% - Auxiliary materials and raw materials account for 8.33% - Other industries account for 1.42% [1]